KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Keryx Biopharmaceutica...
August 08 2016 - 1:23PM
The Law Offices of Vincent Wong announce that a class action
lawsuit has been commenced in the USDC for the Southern District of
New York on behalf of investors who purchased
Keryx
Biopharmaceuticals, Inc. (NASDAQ:KERX) securities February
25, 2016 and August 1, 2016.
Click here to learn about the case:
http://www.wongesq.com/pslra/keryx-biopharmaceuticals.
There is no cost or obligation to you.
According to the complaint, throughout the Class
Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts
about the Company’s business, operations, and prospects.
Specifically, Defendants made false and/or misleading statements
and/or failed to disclose: (1) that the Company was experiencing
production-related difficulties in converting API to finished drug
product; (2) that the issue was resulting in decreased production
yields of finished drug product; (3) that, as a result, the Company
would, and did exhaust its reserve of finished drug product; and
(4) that, as a result of the foregoing, Defendants’ statements
about Keryx’s business, operations, and prospects, were false and
misleading and/or lacked a reasonable basis.
If you suffered a loss in Keryx
Biopharmaceuticals you have until October 3, 2016 to request that
the Court appoint you as lead plaintiff. Your ability to share in
any recovery doesn’t require that you serve as a lead plaintiff. To
obtain additional information, contact Vincent Wong, Esq. either
via email vw@wongesq.com, by telephone at 212.425.1140, or visit
http://www.wongesq.com/pslra/keryx-biopharmaceuticals.
Vincent Wong, Esq. is an experienced attorney
that has represented investors in securities litigations involving
financial fraud and violations of shareholder rights.
Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024